Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.
Official title: A Multiple Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tablet and Capsule Formulations of LY3502970 in Healthy Overweight and Obese Participants
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2023-04-26
Completion Date
2023-11-13
Last Updated
2026-07-10
Healthy Volunteers
Yes
Interventions
LY3502970
Administered orally.
Locations (3)
LabCorp CRU, Inc.
Daytona Beach, Florida, United States
Labcorp Clinical Research LP
Dallas, Texas, United States
LabCorp CRU, Inc.
Madison, Wisconsin, United States